Apnimed, Inc. (APMD) vs Iambic Therapeutics, Inc. (IAM)

Apnimed, Inc. APMD 15.08 +6.50%
Iambic Therapeutics, Inc. IAM 10.20 −12.37%

Apnimed, Inc. and Iambic Therapeutics, Inc. are both Biotechnology companies. Apnimed, Inc. and Iambic Therapeutics, Inc. are of similar size ($589.5M and $551.7M).

Metric	APMD	IAM	Biotechnology median
P/E	0.76	—	10.60
P/S	0.62	—	9.40
P/B	n/m	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	(0.18)	—	9.02
Earnings yield	130.86%	—	(32.88%)
Free cash flow yield	(115.77%)	—	(23.13%)

Metric	APMD	IAM	Biotechnology median
Gross margin	94.53%	—	68.51%
Operating margin	19.88%	—	0.00%
Net margin	81.56%	—	0.00%
Free cash flow margin	(71.50%)	—	0.00%
Return on equity	0.00%	—	(51.96%)
Return on assets	0.00%	—	(46.06%)
Return on invested capital	0.00%	—	0.00%

Metric	APMD	IAM	Biotechnology median
Revenue growth (TTM)	—	—	6.76%
EPS growth (last fiscal year)	(14.69%)	—	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	—	—	0.00%

Metric	APMD	IAM	Biotechnology median
Debt to equity	(0.45)	—	0.00
Current ratio	5.19	—	4.97
Net debt to EBITDA	0.02	—	1.01

Metric	APMD	IAM	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	APMD	IAM	Biotechnology median
Market cap	589.49m	551.74m	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack